plantmad
vaccin
influenza
virus
perhap
poster
children
molecular
farm
mani
candid
vaccin
made
plant
shown
efficaci
anim
model
candid
pandem
viru
vaccin
made
scale
million
dose
less
month
vaccin
suitabl
outbreak
virus
similarli
see
efficaci
homolog
challeng
shown
mice
ferret
chicken
efficaci
heterolog
challeng
high
pathogen
avian
influenza
hpai
strain
work
direct
toward
protect
human
potenti
pandem
influenza
virus
often
overlook
vaccin
candid
could
equal
use
bird
swine
inde
break
chain
recycl
influenza
virus
seem
occur
intens
farm
pig
prime
goal
one
target
plantmad
influenza
vaccin
includ
potenti
hors
group
investig
potenti
make
influenza
pandem
rapid
respons
vaccin
south
africa
make
influenzaviru
haemagglutinin
transient
express
n
success
open
possibl
make
ha
reagent
potenti
vaccin
mean
hitherto
avail
africa
went
use
portion
protein
viruslik
particl
vlp
base
display
vehicl
plant
manufactur
highli
conserv
ectop
epitop
elicitor
broadli
neutralis
antibodi
influenzaviru
strain
candid
univers
vaccin
human
vaccin
protect
rabi
virus
earli
target
molecular
farm
earli
suggest
plantmad
rabi
vaccin
could
use
tool
wildlif
immunis
specif
context
fruit
bat
genu
pteropu
host
mani
potenti
humaninfect
virus
includ
henipavirus
hendra
nipah
menangl
tioman
rubulavirus
australian
bat
lyssaviru
close
rel
rabi
inde
intraperiton
immunis
mice
purifi
extract
transgen
tobacco
nicotiana
tabacum
express
high
concentr
rabi
viru
g
protein
elicit
compar
level
immun
respons
inactiv
convent
vaccin
complet
protect
immun
mice
intracerebr
lethal
challeng
live
rabi
recent
studi
sheep
protect
live
viru
challeng
oral
immunis
singl
dose
transgen
maiz
kernel
contain
mg
g
canadian
biotech
compani
medicago
inc
also
patent
rabi
viruslik
particl
vaccin
made
announc
expans
vaccin
pipelin
includ
new
also
possibl
produc
effect
antirabi
monoclon
antibodi
mab
potenti
biolog
replac
rabi
immunoglobulin
rig
either
equin
human
origin
normal
use
rabi
immunotherapi
prohibit
expens
develop
countri
highli
attract
prospect
futur
develop
respons
seen
press
health
need
rabiesendem
develop
countri
council
scientif
industri
research
south
africa
produc
soontob
commercialis
antirabi
mab
call
rabivir
transgen
tobacco
claim
time
cheaper
convent
ebolavirus
part
one
health
think
time
sever
review
recent
year
discuss
control
virus
emerg
context
one
health
context
zoonot
threat
exot
anim
obviou
target
control
human
also
possibl
primat
risk
like
chimpanze
gorilla
vaccin
one
area
hope
recent
west
african
epidem
acceler
licensur
test
threw
sever
like
candid
one
real
success
recombin
vesicular
stomat
viru
rvsvzebov
notwithstand
subunit
vaccin
may
yet
use
zair
ebola
marburgvirus
investig
done
vaccin
potenti
differ
viral
protein
throw
use
candid
includ
well
obviou
envelop
glycoprotein
toward
goal
sever
plantmad
antigen
shown
potenti
one
novel
approach
express
ebola
immun
complex
eic
n
benthamiana
use
replic
geminivirusderiv
protein
zair
ebolaviru
cterminu
fuse
heavi
chain
humanis
igg
mab
antibodi
specif
bind
coexpress
light
chain
assembl
mab
chimaera
purifi
ammonium
sulfat
precipit
protein
g
affin
chromatographi
mab
function
term
bind
chimaera
form
crosslink
immun
complex
balbc
mice
immunis
subcutan
purifi
eic
produc
antibodi
level
similar
elicit
use
vlp
vaccin
anoth
recent
approach
make
ebolaviru
matrix
protein
protein
highli
multifunct
elicit
protect
immun
transgen
tobacco
plant
express
ertarget
level
mgkg
fresh
weight
plant
tissu
protein
given
oral
subcutan
balbc
mice
lowdos
prepar
ng
oral
ng
sc
without
adjuv
elicit
reason
respons
protein
candid
vaccin
candid
lowcost
reagent
ebolaviru
diagnost
kit
perhap
crown
achiev
molecular
farm
recent
year
one
specif
relat
recent
west
african
zair
ebolaviru
outbreak
product
eventu
acceler
clinic
trial
humanis
mab
cocktail
known
mapp
biopharmaceut
made
transient
express
n
thoroughli
describ
suffic
say
one
product
done
term
rais
profil
plantproduc
pharmaceut
product
gener
therapeut
particular
clinic
trial
west
africa
trial
particip
randomli
assign
studi
arm
mortal
particip
lower
percent
mortal
particip
receiv
standardofcar
alon
percent
mortal
statist
signific
particip
number
low
particip
elimin
viru
bloodstream
faster
rapid
resolut
symptom
discharg
care
earlier
untreat
particip
given
appar
success
us
govern
fund
kentucki
bioprocess
stockpil
mab
mapp
go
ahead
licens
therapeut
use
subsequ
ebola
diseas
note
mab
also
highli
use
diagnost
arena
inexpens
vaccin
made
profit
small
scale
one
drawcard
use
molecular
farm
gener
appreci
reagent
world
danger
zoonot
pathogen
also
expens
hard
danger
make
need
reagent
exemplifi
recent
larg
studi
seropreval
human
nigeria
tickborn
crimeancongo
hemorrhag
fever
bunyaviru
cchfv
south
africa
routin
detect
antibodi
anim
human
cchfv
done
use
nucleoprotein
n
elisa
test
make
protein
hazard
expens
process
involv
fraction
live
viru
prepar
cchfv
infect
cell
cultur
brain
tissu
inocul
suckl
mice
high
biosafeti
condit
also
prepar
recombin
protein
insect
mammalian
cell
method
expens
protein
yield
qualiti
often
good
group
accordingli
use
agrobacteriummedi
transient
express
n
benthamiana
plant
codonoptimis
cchfv
n
gene
encod
genomeassoci
nucleoprotein
np
make
ntermin
np
yield
protein
kg
fresh
plant
materi
solubl
easili
purifi
combin
ammonium
sulfat
precipit
immobilis
metal
ion
chromatographi
protein
use
antiigg
elisa
standard
panel
serum
sampl
collect
post
infect
patient
confirm
anticchfv
igg
use
commerci
immunofluoresc
antibodi
test
serum
sampl
volunt
cchfv
infect
histori
use
neg
control
panel
plantproduc
np
detect
anticchfv
igg
posit
serum
sampl
neg
serum
sampl
gave
result
cutoff
valu
result
suggest
recombin
np
express
plant
signific
potenti
use
diagnosi
surveil
probabl
better
easili
produc
purifi
reagent
avail
present
anoth
innov
approach
express
synthet
cchfv
envelop
glycoprotein
precursor
gcgn
polyprotein
leav
induc
hairi
root
transgen
tobacco
plant
materi
immunogen
mice
via
oral
parenter
immunis
rout
gcgn
purifi
plant
excel
elisa
plate
coat
antigen
detect
envelop
glycoproteinspecif
antibodi
elicit
plantmad
convent
rift
valley
fever
bunyaviru
rvfv
mosquitotransmit
pathogen
livestock
caus
abort
storm
sheep
goat
potenti
lethal
human
expand
geograph
rang
africa
arabia
matter
concern
one
health
movement
effect
veterinari
vaccin
necessarili
safe
licens
human
although
experiment
candid
safer
anim
may
suitabl
human
plantmad
approach
rvfv
vaccin
publish
recent
describ
express
transgen
arabidopsi
thaliana
n
protein
solubl
version
gn
oral
dose
fresh
transgen
plant
materi
immunogen
mice
elicit
system
antigenspecif
igg
augur
well
similar
experi
larger
anim
spur
deploy
human
vaccin
rvfv
could
recent
find
viru
may
involv
human
miscarriag
south
laboratori
process
test
transientlyexpress
rvfv
n
protein
suitabl
diagnost
reagent
similar
cchfv
case
describ
west
nile
flaviviru
wnv
mosquitotransmit
pathogen
famili
zika
yellow
fever
japanes
enceph
virus
also
concern
one
health
given
recent
intercontinent
transmiss
europ
america
fact
viru
transmit
regularli
livestock
human
caus
sever
potenti
use
vaccin
candid
consist
domain
iii
e
glycoprotein
produc
ertarget
transient
express
n
benthamiana
level
mgkg
easili
purifi
bound
mab
recogn
conform
epitop
nativ
protein
elicit
potent
system
immun
respons
subcutan
immun
work
group
provid
evid
humanis
mab
wnv
e
protein
could
produc
n
benthamiana
transient
agroinfiltrationmedi
express
protect
mice
wnvinduc
mortal
compar
mammaliancellproduc
later
work
demonstr
wnv
domain
iii
diii
protein
mab
could
rapidli
produc
high
level
plant
easili
purifi
could
use
identifi
wnv
detect
human
igm
respons
wnv
infect
serolog
fact
mab
crossreact
flavivirus
make
use
diagnost
also
potenti
use
therapi
like
caus
antibodydepend
enhanc
ade
infect
relat
flavivirus
yellow
fever
zika
dengu
virus
dengu
virus
denv
problemat
vaccin
target
given
antibodi
direct
one
dengu
subtyp
protect
infect
other
may
fact
result
ade
infect
result
dengu
hemorrhag
fever
licens
quadrival
live
new
concern
interact
dengu
flavivirus
particular
zika
viru
possibl
reciproc
ade
prompt
caution
use
reason
subunit
vaccin
consist
e
protein
diii
similar
wnv
exampl
serotypespecif
elicit
neutralis
antibodi
involv
ade
triall
monkey
good
efficaci
howev
protein
vaccin
product
probabl
expens
group
base
korea
accordingli
explor
varieti
option
produc
diiideriv
vaccin
plant
includ
fusion
diii
cholera
toxin
b
subunit
ctb
product
transgen
tobacco
fuse
consensu
diii
elicit
neutralis
antibodi
dengu
viru
serotyp
celltarget
peptid
ligand
produc
transgen
rice
calli
show
target
mucos
immun
system
mice
modifi
recombin
immun
complex
ric
shown
work
zair
ebolaviru
fuse
ebola
epitop
bind
mab
dengu
viru
consensu
diii
domain
mab
produc
transient
purifi
hybrid
dengueebola
ric
deric
bound
elicit
potent
virusneutralis
ab
mice
without
use
adjuv
anoth
group
use
transplastom
tobacco
produc
serotyp
diii
protein
moder
yield
without
test
work
show
possibl
produc
candid
dengu
subunit
vaccin
plant
least
equival
conventionallyproduc
candid
potenti
therapeut
product
treatment
dengu
infect
mab
neutral
serotyp
problem
product
mammalian
cell
howev
mab
exhibit
ade
mean
treat
anim
suscept
sever
diseas
infect
anoth
serotyp
product
mab
agroinfiltrationmedi
transient
express
n
benthamiana
howev
abrog
ade
activ
without
affect
antigen
bind
neutralis
effici
denv
serotyp
presum
due
differ
nglycosyl
pattern
compar
convent
mab
properti
could
exploit
therapeut
mab
modul
reduct
fcmediat
function
may
advantag
live
attenu
yellow
fever
viru
yfv
vaccin
efficaci
regard
safe
sinc
credit
save
possibl
million
live
howev
produc
egg
mean
individu
egg
allergi
may
safe
receiv
vaccin
rare
seriou
risk
neurolog
effect
organ
failur
recommend
children
month
elderli
immunocompromis
pregnant
breastfeed
women
receiv
also
concern
immun
dengu
reaction
zika
viru
infect
could
exacerb
prior
immun
yfv
exist
live
monotyp
lifelong
highli
success
vaccin
probabl
dampen
research
enthusiasm
research
subunit
altern
interest
molecular
farm
contract
manufactur
ibio
inc
collabor
fiocruzbiomanguinho
brazil
use
proprietari
technolog
manufactur
plantmad
yfv
technolog
know
molecular
farm
truli
come
age
recent
mani
product
proof
efficaci
anim
model
especi
veterinari
use
review
viru
vaccin
see
howev
proof
principl
anim
human
product
licens
use
human
therapeut
product
includ
elelyso
enzym
replac
therapi
glucocerebrosidas
deficit
caus
gaucher
diseas
human
feel
sphere
interest
one
health
though
molecular
farm
could
truli
make
immedi
impact
applic
plantmad
protein
inexpens
reagent
could
revolutionis
pointofcar
diagnost
exampl
use
farm
vaccin
could
protein
use
diagnost
could
also
make
univers
vaccin
livestock
certain
diseas
realiti
vaccin
anim
safe
human
case
rvfv
cchfv
plantmad
subunit
vaccin
may
safe
bridg
humananim
divid
plantmad
influenzaviru
vaccin
whether
typespecif
univers
could
soon
realiti
may
make
vaccin
swine
poultri
much
easier
cheaper
safer
prospect
rabi
vaccin
especi
therapeut
would
worthi
target
given
anim
human
victim
diseas
develop
countri
also
possibl
molecular
farm
could
allow
routin
applic
therapeut
veterinari
medicin
given
low
cost
good
potenti
oral
dose
brief
review
hope
illustr
exist
arsen
plantmad
vaccin
reagent
suitabl
use
one
health
context
also
potenti
plant
plant
cell
system
use
pathogen
purpos
